LSD for anxiety and depression? Some early studies show promise. Researchers are investigating whether the drug could be used in mainstream medicine—with and without its hallucinatory effects.

Foremost among the #psychedelicmedicines being studied, #LSD has the biggest branding problem. But recent research points to the counterculture's drug's potentially strong benefits, with or without the high. Paywalled NatGeo piece but I'm happy to send PDFs www.nationalgeographic.com/health/artic...

Psychedelic merger to create AtaiBeckley completes A $390m merger of two pioneers of psychedelic medicines has completed to create AtaiBeckley, with a pipeline of candidates for mental illnesses

A $390m merger of two pioneers of #psychedelicmedicines has completed to create #AtaiBeckley, with a pipeline of candidates for #mentalillnesses.
pharmaphorum.com/news/psyched...

Dr Carlson, Dr Ronald Shore are studying how #therapy can be combined with #psychedelicmedicines like psilocybin to offer faster, more effective help. Early trials have shown that even a single dose of #psilocybin can relieve symptoms like depression. Better yet, that relief can last for years.

UK specialists call for more testing on psychedelics UK psychiatrists have called for a relaxation of restrictive rules on testing psychedelics, which are holding back research and clinical use.

The #UK's Royal College of #Psychiatrists (RCPsych) has published a report that calls for more clinical testing of #psychedelicmedicines, as there is currently a lack of "high-quality evidence" to support their use.

pharmaphorum.com/news/uk-spec...

Psychedelic drug stocks surged after Bloomberg News reported AbbVie is in talks to acquire Gilgamesh Pharmaceuticals in a ~$1B deal.

#ATAI #CMPS #MNMD #ATAIStock #CMPSStock #MNMDStock #Psychedelic #PsychedelicDrugs #PsychedelicStocks #PsychedelicMedicines
$ATAI $CMPS $MNMD $ABBV

Beckley psychedelic hits the target, unlocking atai merger The proposed merger between Beckley Psytech and atai is unlocked as a psychedelic for depression hits all its endpoints in a phase 2b trial.

UK #psychedelicmedicines developer #BeckleyPsytech is preparing to take its psychedelic medicine for severe #depression into a pivotal trials programme on the back of a positive phase 2b readout.

My latest in the @thenvindy.bsky.social #psychedelicmedicines